

## COVID-19 Press Briefing

August 27, 2021







### Daily Change in COVID-19 Cases, US

January 22, 2020 – August 25, 2021

TOTAL Cases Reported Since 1/22/20

38,341,339

NEW Cases Reported to CDC on 8/25/21

164,952

Change in 7-Day Case Average


+2.8%

Current 7-Day Case Average (8/19/21 - 8/25/21)

142,006

Prior 7-Day Case Average (8/12/21 - 8/18/21)

138,087







### New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – August 24, 2021

Patients Currently Hospitalized with COVID on 8/24/21

89,770

New Admissions on 8/24/21

12,863

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


+5.7%

Current 7-Day Average of New Admissions (8/18/21 - 8/24/21)

12,297

Prior 7-Day Average of New Admissions (8/11/21 - 8/17/21)

11,637







### Daily Change in COVID-19 Deaths, US

January 22, 2020 – August 25, 2021

TOTAL Deaths Reported Since 1/22/2020

631,440

NEW Deaths Reported to CDC on 8/25/21 1,229

Change in 7-Day Death Average

+11.0%

Current 7-Day Death Average (8/19/21 - 8/25/21)


864

Prior 7-Day Death Average (8/12/21 - 8/18/21)

779

Forecasted Total Deaths by 9/18/21

651,000 to 680,000







# COVID-19 Vaccine Efficacy and Safety in Adolescents







Volume 385

July 15, 2021

Number 3

#### Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents

RW Frenck, Jr., WC Gruber et al. for the C4591001 Clinical Trial Group

- N= 2,260 adolescents 12 to 15 years
- Favorable safety profile, produced a greater immune response than in young adults
- Vaccine efficacy = 100%



Published online August 11, 2021

#### Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

K Ali, R McPhee et al.

- TeenCOVE study of Moderna vaccine; n = 3,732 adolescents 12 to 17 years
- 100% vaccine efficacy against COVID-19 14 days after 2nd dose (small number of endpoints)
- No serious adverse events related to vaccine





# Pfizer-BioNTech COVID-19 Vaccine (BNT162b2, Comirnaty®) for Adolescents

- FDA issued an Emergency Use Authorization (EUA) for use in persons aged ≥16 years on December 11, 2020
- EUA was expanded to include adolescents aged 12-15 years on May 10, 2021, based on results from a Phase 3 clinical trial
- Vaccine fully licensed by FDA for persons aged ≥16 years on August 23, 2021
  - Vaccine continues to be available under EUA for adolescents 12 through 15 years of age







Moderna requested EUA for mRNA-1273 vaccine for adolescents ages 12 to 17 on June 10, 2021; FDA decision pending





# Safety of COVID-19 Vaccines in Adolescents

Mild Local and Systemic Reactions are Common Among Adolescents

Serious Adverse Events are Rare







Morbidity and Mortality Weekly Report

Weekly July 9, 2021 Vol. 70 No. 27

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021

Weekly August 6, 2021 Vol. 70 No. 31

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021

Weekly August 13, 2021 Vol. 70 No. 32

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna):

Update from the Advisory Committee on Immunization

Practices — United States, July 2021



# Reasons for Adolescents to Be Vaccinated Against COVID-19

- COVID-19 vaccines are safe, effective, convenient..... and free
- Protect yourself from COVID-19
- Help protect family members, friends, classmates, teachers and other important people your life
  - Some of them may be especially vulnerable to COVID-19 complications, and you may not know it









THE WHITE HOUSE WASHINGTON

### WH.GOV